Answers are grounded in this paper and cite their sources.
Diagnosing inflammatory bowel disease (IBD) is based on a combination of clinical symptoms, with laboratory tests and endoscopy, to distinguish IBD from other conditions. Faecal amino acids, particularly leucine, have shown promising results as noninvasive biomarker for this purpose. This cross-sectional study evaluated faecal leucine and the leucine/isoleucine ratio and its potential discriminative value between treatment-naïve IBD patients and patients with irritable bowel syndrome (IBS) and functional abdominal pain- not otherwise specified (FAP-NOS) patients, using a targeted liquid chromatography-mass spectrometry (LC-MS/MS) technique. Absolute leucine concentration and the leucine/isoleucine ratio were significantly higher in IBD, with the leucine/isoleucine ratio showing an area under the curve of 0.75 (95%CI: 0.65-0.84) with a cut-off value of 1.44. Concluding, the leucine/isoleucine ratio can differentiate IBD from IBS and FAP-NOS, and provides insights into disease pathogenesis. These findings highlight its potential as a novel noninvasive biomarker, although further studies are warranted.
No takes yet. Share an insight, caveat, or question.
Verstoep et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: